This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva (TEVA) Stock Poised to Record Big Gains in 2019?
by Zacks Equity Research
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
Generic Drugmakers Down on Allegations of Price Fixing
by Zacks Equity Research
An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
by Zacks Equity Research
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
Mylan Expands Recall of Valsartan to All Unexpired Lots
by Zacks Equity Research
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Novartis' Gilenya Approved in EU for Expanded Population
by Zacks Equity Research
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
by Zacks Equity Research
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
4 Reasons Why Lilly is Up More Than 30% This Year So Far
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 33.7% this year so far. Let us have a look at the reasons for the same.
J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down
by Zacks Equity Research
A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment
by Zacks Equity Research
Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Regeneron (REGN) Rides on Eylea and Dupixent's Performance
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Lilly Offers Updates on Progress of Headache Disorder Drugs
by Zacks Equity Research
Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.
Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
by Zacks Equity Research
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
by Zacks Equity Research
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Teva (TEVA) Beats on Q3 Earnings, Lags Sales, Shares Up
by Zacks Equity Research
Teva's (TEVA) third-quarter earnings beat estimates but sales miss expectations. Teva tightens its 2018 guidance for sales while raising the same for earnings. Shares rise in pre-market trading.
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.